Richard H Isaacs

US Patent:

6387911, May 14, 2002

Filed:

Nov 21, 2000

Appl. No.:

09/717566

Inventors:

Christopher Burgey - Philadelphia PA
Richard C. Isaacs - Harleysville PA
Bruce D. Dorsey - Maple Glen PA
Kyle A. Robinson - Elkins Park PA
Donnette Staas - Lansdale PA
Philip E. Sanderson - Philadelphia PA
James Barrow - Harleysville PA

Assignee:

Merck Co., Inc. - Rahway NJ

International Classification:

A61K 31497

US Classification:

51425505, 544405

Abstract:

Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the following structure: or a pharmaceutically acceptable salt thereof, wherein A is.

US Patent:

6462050, Oct 8, 2002

Filed:

Jul 27, 2001

Appl. No.:

09/916745

Inventors:

Richard C. Isaacs - Harleysville PA
Kellie Cutrona - Harleysville PA
James C. Barrow - Harleysville PA
Harold G. Selnick - Ambler PA

Assignee:

Merck Co., Inc. - Rahway NJ

International Classification:

A61K 31497

US Classification:

51425505, 544405

Abstract:

Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions having the following structure:.

US Patent:

7741322, Jun 22, 2010

Filed:

Sep 17, 2004

Appl. No.:

10/571858

Inventors:

Christopher J. Dinsmore - Schwenksville PA, US
Jeffrey M. Bergman - Sellersville PA, US
Charles J. McIntyre - Lansdale PA, US
Richard Isaacs - Harleysville PA, US
David A. Claremon - Maple Glen PA, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/4725
C07D 401/12

US Classification:

5142352, 514309, 544128, 546141

Abstract:

The present invention relates to compounds having the structure (I) useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.

US Patent:

7763614, Jul 27, 2010

Filed:

Sep 22, 2004

Appl. No.:

10/572236

Inventors:

Richard Isaacs - Harleysville PA, US
Christopher J. Dinsmore - Newton MA, US
B. Wesley Trotter - Glenside NJ, US
Nigel Liverton - Harleysville PA, US
Douglas C. Beshore - Harleysville PA, US
Nathan R. Kett - Perkiomenville PA, US
Charles J. McIntyre - Lansdale PA, US
Kausik K. Nanda - Norristown PA, US
David A. Claremon - Maple Glen PA, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07D 401/02
A61K 31/47

US Classification:

5142352, 51425305, 514256, 514309, 544128, 544242, 544363, 546141

Abstract:

The present invention relates to compounds of structural formula I: I useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.

US Patent:

7781457, Aug 24, 2010

Filed:

Sep 22, 2004

Appl. No.:

10/572343

Inventors:

Richard Isaacs - Harleysville PA, US
Christopher J. Dinsmore - Schwenksville PA, US
Charles J. McIntyre - Lansdale NJ, US
Linda S. Payne - Lansdale PA, US
David A. Claremon - Maple Glen PA, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

C07D 217/16
A61K 31/47

US Classification:

514309, 546141

Abstract:

The present invention relates to compounds having the structure formula (I) useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.

US Patent:

7906521, Mar 15, 2011

Filed:

Sep 17, 2004

Appl. No.:

10/572341

Inventors:

B. Wesley Trotter - Glenside PA, US
Richard Isaacs - Harleysville PA, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ

International Classification:

A61K 31/517
C07D 239/88
C07D 239/90
C07D 239/91

US Classification:

51426631, 544285, 544287, 544290

Abstract:

The present invention relates to compounds useful as potassium channel inhibitors to treat cardiac arrhythmias, and the like.

US Patent:

20070179196, Aug 2, 2007

Filed:

Mar 9, 2005

Appl. No.:

10/587682

Inventors:

Wei Han - West Chester PA, US
Melissa Egbertson - Ambler PA, US
John Wai - Harleysville PA, US
Linghang Zhuang - Chalfont PA, US
Rowena Ruzek - North Wales PA, US
Debra Perlow - East Greenville PA, US
Richard Isaacs - Harleysville PA, US
Mark Cameron - Brick NJ, US
Bruce Foster - Scoth Plains NJ, US
Ulf Dolling - Westfield NJ, US
R. Hoermer - Westfield NJ, US
Vanessa Obligado - Oreland PA, US
Lou Neilson - Sellersville PA, US
Boyoung Kim - Lansdale PA, US
Linda Payne - Lansdale PA, US
Matthew Morrissette - Radnor PA, US
Peter Williams - Harleysville PA, US
Philip Pye - Guttenberg NJ, US
Remy Angelaud - Union NJ, US
Danny Mancheno - Rego Park NY, US
David Askin - Warren NJ, US

International Classification:

A01N 37/08

US Classification:

514530000

Abstract:

Hydroxy (tetra- or hexa-)hydronaphthyridine dione compounds of Formula I are inhibitors of HIV integrase and inhibitors of HIV replication: (I) wherein a, R,1?, R,2?, R,3?, R,4? and R,5? are defined herein. The compounds are useful in the prevention and treatment of infection by HIV and in the prevention, delay in the onset, and treatment of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

US Patent:

20090054399, Feb 26, 2009

Filed:

May 5, 2006

Appl. No.:

11/920032

Inventors:

Joseph P. Vacca - Telford PA, US
John S. Wai - Harleysville PA, US
Linda S. Payne - Lansdale PA, US
Richard C.A. Isaacs - Harleysville PA, US
Wei Han - West Chester PA, US
Melissa Egbertson - Ambler PA, US
Richard Pracitto - SanDiego CA, US

International Classification:

A61K 31/5383
C07D 471/14
A61K 31/551
A61K 31/4985
A61K 31/4375
C07D 498/14

US Classification:

51421104, 540497, 514220, 514250, 544346, 514293, 546 82, 540488

Abstract:

Tricyclic compounds of Formula (I) are inhibitors of HIV integrase and inhibitors of HIV replication: wherein bond a, ring A, R, Rand Rare defined herein. The compounds are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.